Enpatoran
- Generic Name
- Enpatoran
Effect of Renal Impairment on Enpatoran Pharmacokinetics
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 40
- Registration Number
- NCT06589713
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Enpatoran Human Mass Balance and Absolute Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 7
- Registration Number
- NCT05110027
- Locations
- 🇳🇱
PRA Health Sciences, Groningen, Netherlands
Study of M5049 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 36
- Registration Number
- NCT04880213
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
Study of M5049 in CLE and SLE Participants
Phase 1
Completed
- Conditions
- Systemic Lupus ErythematosusCutaneous Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 25
- Registration Number
- NCT04647708
- Locations
- 🇩🇪
SocraTec R&D GmbH, Erfurt, Germany
🇩🇪Fraunhofer ITMP (Fraunhofer Institute for Translational Medicine and Pharmacology), Frankfurt, Germany
🇧🇬Medical Center-1-Sevlievo EOOD, Sevlievo, Bulgaria
Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)
- First Posted Date
- 2020-06-26
- Last Posted Date
- 2022-06-06
- Target Recruit Count
- 149
- Registration Number
- NCT04448756
- Locations
- 🇺🇸
Holy Name Hospital - Dept of Multiple Sclerosis Comp Care Center, Teaneck, New Jersey, United States
🇧🇷Hospital Dia do Pulmão, Blumenau, Brazil
🇧🇷Instituto de Infectologia EmÃlio Ribas, São Paulo, Brazil
Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of M5049 in Healthy Participants
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 96
- Registration Number
- NCT03676322
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath